Proteomics International has an unparalleled scientific and commercial team from a diverse range of backgrounds. The team has skills in all aspects of protein chemistry encompassing the cutting edge of mass spectrometry to traditional methods and more.
Richard has extensive experience in analysing biomolecules by proteomics techniques, in particular mass spectrometry, including over 25 years research experience in academic and commercial organisations. As a founding Director and Managing Director of Proteomics International Richard has overseen the commercial and technical development of the organisation. Previously he was Manager of the core Protein Analysis Facility at the University of Western Australia, following a post-doctoral position at the Institute for Child Health Research. He is company trained in the use of MALDI-TOF MS and LC/MS/MS (including TOF/TOFs and ion-traps), and further expertise/training in Edman sequencing, peptide synthesis, and robotics for proteomics.
1995 PhD (Immunology), University of London (Institute of Child Health)
1991 Certificate in Immunology, Kings College, University of London
1990 MA and BA (Chemistry), Corpus Christi College, Oxford University
Pearl joined Proteomics International in 2013, and is now responsible for the day-to-day operations management and execution of company strategies. She is also responsible for managing the business development and product development of PromarkerD, the company’s predictive diagnostic test for diabetic kidney disease.
Pearl has a background in Research, focusing on Biochemistry and Molecular Biology. She dedicated her career to the biotechnology industry following her involvement in an Industry-Research Collaboration (Researchers in Business Grant) between Proteomics International and UWA, to commercialise a patented technology for measuring oxidative stress.
2013 PhD (Research), Biochemistry and Molecular Biology, UWA
2008 BSc with honours in Biochemistry, UWA, Australia
2007 BSc, Molecular Biology and Biotechnology, UWA, Australia
Scott is responsible for all Research areas within Proteomics International. This involves oversight of Biomarker discovery and development projects encompassing PromarkerD, PI’s predictive test for diabetic nephropathy. Alongside the biomarker research program is the development and implementation of novel methods for examining biological systems (particularly venoms) for discovery of novel therapeutic peptides where genomic/ proteomic information is unavailable or incomplete. He also leads the development of new chromatographic and mass spectrometric methods for handling of complex biological samples for analysis and investigation.
Scott has a commercial background as proteomics scientist and mass spectrometry specialist at a New Zealand based R&D company, now part of AgResearch. This was preceded by a Post-Doctoral Fellowship at the National Cancer Institute, USA, looking at bioactive protein isolation, purification and identification of both anti-cancer and anti-HIV leads from marine sources. Scott’s skills are wide ranging and include expertise with mass spectrometers, liquid chromatography, assay development and bioinformatic analysis.
2001 PhD, Department of Chemistry, University of Canterbury
1997 BSc (Hons), Department of Chemistry, University of Canterbury
Chuck has over 36 years experience in life sciences, biotechnology, and diagnostic industries. Chuck has an undergraduate degree in chemistry and an MBA from Boston University. He has held several management positions while at NEN Life Sciences and DuPont before focusing his last 15 years in Business Development at PerkinElmer. Chuck has successfully executed many licensing deals and several global acquisitions while in this role. Chuck is based in Massachusetts, USA and started working with the Company in May 2014.
MBA, Boston University, Massachusetts, USA
Shane Herbert joined Proteomics International in June 2017 as the Customer Services Manager and undertakes the role of Study Director, managing the company’s pharmacokinetics, biosimilars/biologics and biomarker projects. He is also tasked with implementing business development strategies for new expanding areas for the company.
Shane combines a strong customer focus and commercial conduct with the technical nature of technology driven services. Shane is experienced in technical training and applications support, project management, forecasting, budgeting and international communication.
Shane has significant commercial Life Sciences experience gained from working with various companies including private biotech, large pharma, commercial instrument vendors and most recently with the Australian Genome Research Facility.
2015 Diploma of Project Management, Parker Brent Institute, Australia
1996 BSc with honours in Biotechnology, Murdoch University, Australia